BeiGene News
- July 2, 2020BeiGene to Host Investor Conference Call and Webcast to Discuss the Company’s Early Development Pipeline and Research
BeiGene to Host Investor Conference Call and Webcast to Discuss the Company’s Early Development Pipeline and Research
- July 1, 2020BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Patients with Previously Treated Unresectable Hepatocellular Carcinoma in China
BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Patients with Previously Treated Unresectable Hepatocellular Carcinoma in China
- July 1, 2020BeiGene Announces Appointment of Angus Grant as Chief Business Executive
BeiGene Announces Appointment of Angus Grant as Chief Business Executive
- June 30, 2020BeiGene Begins Commercializing XGEVA® (Denosumab) in China
BeiGene Begins Commercializing XGEVA® (Denosumab) in China
- June 22, 2020BeiGene and SpringWorks Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b/2 Clinical Trial
BeiGene and SpringWorks Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b/2 Clinical Trial
- June 19, 2020BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Non-Squamous Non-Small Cell Lung Cancer in China
BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Non-Squamous Non-Small Cell Lung Cancer in China
- BeiGene Facts
- 2010Founded
- NASDAQ: BGNE
HKEX: 06160Listings - 6Internally Developed
Clinical Candidates - 3Marketed
Products
in China - 1Approved
products
in the U.S. - 3000+Global Team
2010
- BeiGene was founded as a research and development company
2012
- Began work on an anti-PD-1 antibody and a BTK inhibitor
2014
- Started clinical trials of pamiparib and zanubrutinib
2016
- Went public on the Nasdaq, with $182 million initial public offering
2018
- Established first European office in Switzerland
- 50+ ongoing or planned clinical trials
2019
- Received first FDA approval for BRUKINSA™ (zanubrutinib)
- Received first approval for tislelizumab in China
Partnering
Partnerships that Extend Around the Globe
BeiGene is the partner of choice in China for development and commercialization. Read more about our current partnerships and opportunities to build business relationships.
Our Patients
Our Commitment to Patients
At BeiGene we are focused not only on the underserved global cancer patient population, but also on individual people fighting their illnesses.